Understanding Pain in Polycystic Ovary Syndrome: Health Risks and Treatment Effectiveness

This retrospective study of over 103 million women using TriNetX data reveals that pain affects approximately 20.67% of women with PCOS, with significant racial disparities in prevalence and associated health risks, while also demonstrating that PCOS-related medications effectively reduce pain diagnoses.

The Gist

Imagine your body is a complex, bustling city. For most people, the city runs smoothly: traffic flows, power grids hum, and the parks are green. But for women with Polycystic Ovary Syndrome (PCOS), it's like the city's central control tower is sending out mixed signals. Hormones get confused, leading to issues like irregular periods, extra hair growth, and trouble getting pregnant.

For a long time, doctors and researchers have focused on the "traffic jams" (reproductive issues) and the "power outages" (metabolic issues like diabetes). But they often ignored the noise and construction happening in the streets: Pain.

This new study is like a massive city-wide survey that finally asked: "How much does it hurt to live in this city, and does the pain change the future of the neighborhood?"

Here is what the researchers found, broken down into simple stories:

1. The "Painful Neighborhood" is Real and Common

The researchers looked at the medical records of over 100 million women (that's like surveying every person in a country the size of China and the US combined). They found that about 1 in 5 women with PCOS are dealing with significant pain—specifically cramps (dysmenorrhea), belly aches, or pelvic pain.

• The Analogy: Think of PCOS as a storm. For some, it's a light drizzle (just irregular periods). For 20% of women, it's a hurricane with heavy winds and debris (severe pain).
• The Disparity: The storm hits some neighborhoods harder than others. The study found that Black and White women with PCOS reported the highest levels of pain (about 30-33%), while Asian women reported less. This suggests that pain isn't just a biological glitch; it might be influenced by genetics, culture, or how different communities access healthcare.

2. Pain is a "Warning Siren" for Future Trouble

The study didn't just look at today; it looked at the future. They asked: "If a woman with PCOS is in pain right now, what does her city look like in 10 years?"

They found that women with PCOS + Pain are walking into a more dangerous future than women with PCOS but no pain.

• The "Double Trouble" Effect: Women with pain were much more likely to develop ovarian cysts (fluid-filled sacs on the ovaries) and liver issues later on.
• The Mental Health Connection: Pain acts like a heavy backpack. Carrying it makes you more likely to drop your mental health. Women with PCOS and pain had significantly higher risks of depression and anxiety compared to those without pain.
• The Twist: Interestingly, women with PCOS without pain were actually at higher risk for infertility and Type 2 Diabetes. This suggests there might be two different "types" of PCOS: one driven by metabolic issues (sugar/weight) and one driven by inflammation and pain.

3. The "Medicine Cabinet" Surprise

Doctors usually prescribe three main tools to fix the PCOS city:

1. Birth Control Pills: To regulate the traffic.
2. Metformin: To fix the power grid (insulin).
3. Spironolactone: To calm the construction noise (lowering male hormones).

The study found a silver lining: These medicines didn't just fix the hormones; they also quieted the pain.

• The Analogy: It's like fixing the city's traffic lights and power grid, and suddenly, the construction noise stops too.
• The Result: After taking these meds, the number of women reporting pain dropped significantly. Spironolactone was the best at stopping belly pain, while birth control pills were best at stopping menstrual cramps. This suggests that treating the root cause of PCOS might be the best way to treat the pain, rather than just popping a painkiller.

4. Why This Matters

For years, if a woman with PCOS complained of pain, doctors might have said, "That's just part of the syndrome, deal with it," or looked for other causes like endometriosis.

This study says: "Stop ignoring the pain."

• Pain is a major symptom that affects a huge number of women.
• Pain is a red flag that a woman might be at higher risk for liver disease, kidney issues, and mental health struggles.
• Treating the PCOS with standard medications often helps the pain, too.

The Bottom Line

Think of PCOS not just as a reproductive issue, but as a whole-body storm. This research tells us that we need to listen to the "noise" (pain) because it tells us exactly which parts of the body are in trouble and how to help them. By treating the pain and the hormones together, we can help women with PCOS build a safer, healthier city for their future.

Technical Summary

1. Problem Statement

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting 8–13% of women of reproductive age, yet approximately 70% remain undiagnosed. While diagnostic criteria and management guidelines focus heavily on reproductive (e.g., infertility, irregular cycles) and metabolic manifestations (e.g., insulin resistance, T2D), the burden of pain (specifically dysmenorrhea, abdominal pain, and pelvic pain) remains underexplored.

• Knowledge Gap: There is insufficient data on the prevalence of pain in PCOS patients compared to non-PCOS controls, how pain correlates with future health outcomes, and whether standard PCOS pharmacotherapies alleviate pain symptoms.
• Hypothesis: Women with PCOS experience a higher prevalence of pain than those without, and this prevalence varies significantly across racial groups. Furthermore, the presence of pain may indicate a distinct clinical phenotype with unique future health risks.

2. Methodology

The study is a large-scale, retrospective cohort analysis utilizing Electronic Health Records (EHR) from the TriNetX Global Network.

• Data Source: Data was extracted on January 9, 2026, from 172 healthcare organizations (HCOs) across 19 countries, covering over 103 million women.
• Cohort Definitions:
  • PCOS Cases: Defined by ICD-10-CM code E28.2, or a combination of irregular menstruation (N92.6) + hirsutism (L68.0) or androgen excess (E28.1).
  • PCOS + Pain Cases: PCOS cases with an additional diagnosis of abdominal/pelvic pain (R10) or dysmenorrhea (N94.6) within ±3 months of the PCOS index event.
  • Controls: Women with a physical exam (Z00.0) but without PCOS or pain criteria.
  • Exclusion Criteria: Conditions that mimic PCOS or cause pain, including endometriosis (N80), uterine fibroids (D25), pelvic inflammatory disease (N73.9), hypothyroidism, hyperprolactinemia, and adrenal hyperplasia.
• Statistical Approach:
  • Propensity Score Matching (PSM): 1:1 matching was performed to control for confounders: age, self-reported race, obesity/overweight status, T2D, hypertension, and hyperlipidemia.
  • Relative Risk (RR): Calculated for 11 future health outcomes (e.g., infertility, ovarian cysts, T2D, depression, anxiety, GERD, kidney/liver disease) occurring >3 months after the index event.
  • Stratification: Analyses were stratified by self-reported race (Asian, Black/African American, White, and "Other").
  • Medication Analysis: Assessed changes in pain diagnosis prevalence before and after the prescription of three common PCOS medications: systemic contraceptives (COCPs), metformin, and spironolactone.

3. Key Contributions

• Quantification of Pain Burden: First large-scale EHR study to quantify the prevalence of pain specifically within the PCOS population, establishing that ~20.67% of PCOS patients report pain.
• Phenotypic Differentiation: Demonstrates that "PCOS with Pain" represents a distinct clinical phenotype with a different risk profile for future comorbidities compared to "PCOS without Pain."
• Racial Disparities: Highlights significant racial heterogeneity in pain prevalence and associated health risks, noting notably higher pain prevalence in Black/African American and White populations compared to Asian populations.
• Treatment Efficacy: Provides evidence that standard PCOS pharmacotherapies (COCPs, metformin, spironolactone) are associated with a reduction in pain diagnoses, suggesting a dual benefit for symptom management.

4. Key Results

A. Prevalence and Demographics

• Overall Prevalence: In the PCOS cohort, 20.67% had a pain diagnosis (17.82% abdominal/pelvic pain; 2.85% dysmenorrhea).
• Racial Stratification: Pain prevalence was highest in Black/African American (32.70%) and White (30.78%) populations, compared to Asian (27.20%).
• Comorbidity Burden: The "PCOS + Pain" cohort showed a 2-fold increase in baseline comorbidities compared to the general PCOS cohort:
  • Obesity: 33.88% (vs. 16.28% in general PCOS).
  • Hypertension: 12.43% (vs. 5.93%).
  • T2D: 7.84% (vs. 3.51%).

B. Future Health Outcomes (Relative Risk)

• PCOS vs. Controls: PCOS patients generally had increased RR for infertility (RR 3.55), T2D (RR 2.77), and obesity (RR 2.00).
• PCOS + Pain vs. Controls:
  • Ovarian Cysts: Significantly higher risk in the pain cohort (RR 2.23) compared to the general PCOS cohort (RR 1.56).
  • Mental Health: The pain cohort had elevated risks for Depression (RR 1.43 vs. 1.23) and Anxiety (RR 1.37 vs. 1.11).
  • GERD: Markedly higher risk in the pain cohort (RR 1.80 vs. 1.32).
  • Infertility: Interestingly, the RR for infertility was lower in the pain cohort (RR 1.04) compared to the general PCOS cohort (RR 3.55), suggesting a potential divergence in pathophysiology or healthcare utilization patterns.
• Racial Differences in Risk:
  • Infertility: Significantly higher RR in Black/African American and "Other" groups compared to Asian and White groups.
  • Kidney Disease: Asian patients with PCOS + Pain showed a decreased RR (0.80), while Black/African American, Other, and White groups showed increased risks.

C. Medication Effectiveness

Analysis of patients prescribed specific medications showed a reduction in pain diagnoses post-prescription:

• Spironolactone: Largest reduction in abdominal/pelvic pain (-9.1%).
• COCPs: Significant reduction in abdominal/pelvic pain (-6.3%) and the largest reduction in dysmenorrhea (-3.8%).
• Metformin: Moderate reduction in abdominal/pelvic pain (-5.3%).

5. Significance and Implications

• Clinical Practice: The study argues for the routine assessment of pain in PCOS management guidelines. Pain is not merely a symptom but a marker for a high-risk phenotype (higher metabolic and mental health risks).
• Health Disparities: The findings underscore critical racial disparities in pain reporting and outcomes, necessitating culturally competent care and targeted interventions for Black/African American and White populations who exhibit higher pain burdens.
• Therapeutic Strategy: The observed reduction in pain with standard PCOS medications suggests that treating the underlying endocrine disorder (e.g., via anti-androgenic effects of spironolactone or cycle regulation via COCPs) effectively manages pain, potentially reducing the need for separate analgesic interventions.
• Future Research: The authors call for longitudinal studies to understand the mechanistic link between pain, inflammation, and metabolic dysregulation in PCOS, and to investigate why the "pain phenotype" shows lower infertility risks despite higher metabolic risks.

Limitations: The study relies on ICD codes which may miss pain severity nuances; it is observational (no causality); and it lacks data on over-the-counter analgesic use or medication adherence.